INNOVENT BIOLGCS UNSP/ADR (IVBIY) analyst actions
Rating and price-target actions on IVBIY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IVBIY overview →
5 measured IVBIY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM) | Press release | — | — | |
| Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3) | Press release | — | — | |
| Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA | Press release | — | — | |
| Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications | Press release | — | — | |
| Innovent's MSCI ESG Rating Upgraded to A | Press release | — | — |
Keep exploring
More IVBIY: earnings → · SEC filings → · IVBIY overview →